Regeneron profit beats estimates on Dupixent strength
Reuters
Published Feb 03, 2023 06:37AM ET
Updated Feb 03, 2023 08:06AM ET
(Reuters) -Regeneron Pharmaceuticals Inc reported a better-than-expected fourth-quarter profit on Friday, as strong demand for eczema drug Dupixent helped shield a drop in U.S. sales of its blockbuster eye drug, Eylea.
Eylea, which recorded total sales of $9.65 billion in 2022, has been a key growth driver for the company ever since its launch more than a decade ago. But analysts have flagged competition from Roche's Vabysmo, which was approved last year.
Sales of Eylea, used to treat vision loss causing age-related macular degeneration, were impacted by temporary closing of a fund during the quarter that provides co-pay assistance to patients. U.S. sales of the drug were down 3.3% to $1.50 billion in the fourth quarter.
However, the company last month said that patients, who had switched to a less expensive alternative, were already beginning to use Eylea again.
Quarterly sales of the company's Dupixent, recorded by its partner Sanofi (NASDAQ:SNY), rose 38% to $2.45 billion, with Regeneron (NASDAQ:REGN)'s collaboration revenue from the French company jumping about 61% to $836 million.
Dupixent is an anti-inflammatory drug, which was approved in 2017, and has also been a booster for Regeneron with the treatment currently approved for five indications, including asthma and atopic dermatitis, or eczema.
Excluding items, the company reported a profit of $12.56 per share for the quarter ended Dec. 31, above analysts' estimates of $10.03, according to Refinitiv IBES data.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.